Regeneron's $953 Million Trading Day Lands 87th in Market Activity

On May 14, 2025, Regeneron's trading volume reached $953 million, marking a 45.43% increase from the previous day, ranking 87th in the day's stock market activity. Regeneron's stock price has declined by 0.49% over the past two days, with a cumulative decrease of 0.74%.

Regeneron Pharmaceuticals, Inc. (REGN) has announced that its board of directors has declared a quarterly dividend of $1.15 per share on the company's common stock. The dividend is payable on June 14, 2025, to stockholders of record at the close of business on May 31, 2025. This dividend declaration reflects the company's strong financial performance and commitment to returning value to its shareholders.

Regeneron has also reported positive results from its Phase 3 clinical trial for a new drug candidate aimed at treating a rare genetic disorder. The trial met its primary endpoint, demonstrating a statistically significant improvement in key clinical measures compared to the placebo group. This success highlights the company's continued innovation in the biopharmaceutical sector and its potential to bring new therapies to patients in need.

Additionally, Regeneron has entered into a strategic collaboration with a leading academic institution to advance research in the field of immunology. This partnership aims to leverage the strengths of both organizations to develop novel therapies for autoimmune diseases, further solidifying Regeneron's position as a leader in the biotechnology industry.